| Data | Hora | Fonte | Título | Código | Companhia |
| 17/11/2017 | 19:07 | Edgar (US Regulatory) | Termination of Registration of a Class of Security Under Section 12(b) (15-12b) | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 14/11/2017 | 09:01 | Edgar (US Regulatory) | Notice of Effectiveness (effect) | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 09/11/2017 | 20:02 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 07/11/2017 | 14:01 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 07/11/2017 | 13:24 | Edgar (US Regulatory) | Amended Statement of Ownership: Solicitation (sc 14d9/a) | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 07/11/2017 | 12:23 | Edgar (US Regulatory) | Post-effective Amendment to an S-8 Filing (s-8 Pos) | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 07/11/2017 | 12:17 | Edgar (US Regulatory) | (25-NSE) | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 07/11/2017 | 12:15 | Edgar (US Regulatory) | Post-effective Amendment to Registration Statement (pos Am) | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 07/11/2017 | 11:57 | Edgar (US Regulatory) | Amended Tender Offer Statement by Third Party (sc To-t/a) | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 07/11/2017 | 11:43 | GlobeNewswire Inc. | Ultragenyx Completes Tender Offer and Acquisition of Dimension Therapeutics | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 06/11/2017 | 19:08 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 26/10/2017 | 10:30 | GlobeNewswire Inc. | Ultragenyx and Dimension Announce Expiration of Hart-Scott-Rodino Waiting Period for Ultragenyx’s Acquisition of Dimension | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 13/10/2017 | 12:18 | PR Newswire (US) | WEISSLAW LLP: Dimension Therapeutics, Inc. Acquisition May Not Be in the Best Interests of DMTX Shareholders | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 10/10/2017 | 09:45 | Edgar (US Regulatory) | Statement of Ownership: Solicitation (sc 14d9) | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 10/10/2017 | 09:34 | Edgar (US Regulatory) | Tender Offer Statement by Third Party (sc To-t) | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 05/10/2017 | 16:48 | PR Newswire (US) | Harwood Feffer LLP Announces Investigation of Dimension Therapeutics, Inc. | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 03/10/2017 | 17:19 | Edgar (US Regulatory) | Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 03/10/2017 | 17:05 | Edgar (US Regulatory) | Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c) | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 03/10/2017 | 11:00 | PR Newswire (US) | Dimension (DMTX) Alert: Johnson Fistel Investigates Proposed Sale of Dimension Therapeutics, Inc.; Are Shareholders Getting a... | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 03/10/2017 | 09:50 | Edgar (US Regulatory) | Written Communication Relating to an Issuer or Third Party (sc To-c) | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 03/10/2017 | 09:30 | GlobeNewswire Inc. | Ultragenyx to Acquire Dimension Therapeutics | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 02/10/2017 | 10:22 | GlobeNewswire Inc. | Ultragenyx Comments on Dimension Therapeutics’ Announcement that Ultragenyx’s Offer is a “Superior Proposal” | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 02/10/2017 | 10:16 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 02/10/2017 | 09:30 | GlobeNewswire Inc. | REGENXBIO Responds to Notification of a Superior Proposal Under Its Merger Agreement With Dimension Therapeutics | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 19/09/2017 | 09:00 | GlobeNewswire Inc. | Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to ... | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 18/09/2017 | 16:10 | GlobeNewswire Inc. | Dimension Confirms Receipt of Unsolicited Proposal from Ultragenyx | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 18/09/2017 | 09:35 | GlobeNewswire Inc. | Ultragenyx Proposes to Acquire Dimension Therapeutics for $5.50 Per Share in Cash | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 05/09/2017 | 07:00 | PR Newswire (US) | OncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP to Board of Directors | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 31/08/2017 | 19:23 | PR Newswire (US) | SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Dimension Therapeutics, Inc. - DMTX | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
| 31/08/2017 | 09:00 | GlobeNewswire Inc. | Dimension Therapeutics Commences Patient Dosing in Global, Multi-Center Phase 1/2 Clinical Trial of DTX301 in Ornithine Trans... | NASDAQ:DMTX | Dimension Therapeutics, Inc. |
